Sanofi SA on Thursday posted higher earnings and sales for the first quarter, driven by best-selling drug Dupixent and consumer healthcare, and said that it expects further growth in business earnings per share during 2022.
The French pharma major posted net profit of 2 billion euros ($2.11 billion) for the quarter, up from EUR1.57 billion the year prior. Sales were EUR9.67 billion, up from EUR8.59 billion the year prior.
Best-selling eczema drug Dupixent alone grew by 45.7% on year, the company said, driving sales in Sanofi’s specialty care business.
Business net income–a key profit metric that excludes some items–clocked in at EUR2.42 billion, from EUR2.02 billion the year prior, Sanofi said. Business earnings per share were EUR1.94, up 20.5% from the prior-year level, the company said.
Looking ahead, Sanofi said it expects 2022 business EPS to grow low-double digit at constant exchange rates, with a positive currency impact of between 4% and 5%.